<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270516</url>
  </required_header>
  <id_info>
    <org_study_id>Diaphragm EPA HMB</org_study_id>
    <nct_id>NCT01270516</nct_id>
  </id_info>
  <brief_title>Effect of EPA and HMB on Strength in ICU Patients</brief_title>
  <official_title>Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gerald Supinski</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will determine if administration of HMB (hydroxymethylbutyrate) or EPA&#xD;
      (eicosapentaenoic acid) will increase diaphragm and limb muscle strength for patients on&#xD;
      breathing machines in an intensive care unit. The investigators will first measure the&#xD;
      strength of the diaphragm and a limb muscle (the quadriceps)using magnetic stimulators to&#xD;
      activate these muscles. Muscle size will be measured by using an ultrasound to measure&#xD;
      diaphragm thickness and quadriceps thickness. The investigators will also perform a vastus&#xD;
      lateralis muscle biopsy. Patients will then be randomized to receive either placebo (saline&#xD;
      30 ml every 12 hours via the GI tract, EPA (1000 mg given every 12 hours via the GI tract),&#xD;
      HMB (1500 mg given every 12 hours via the GI tract), or the combination of EPA (1000 mg given&#xD;
      every 12 hours via the GI tract) and HMB (1500 mg given every 12 hours via the GI tract).&#xD;
      Drugs will be given for 10 days; at the end of this time (on day 11), strength measurements,&#xD;
      ultrasound muscle size measurements, and the vastus lateralis biopsy will be repeated. On day&#xD;
      21 an additional followup set of diaphragm and quadriceps strength and size measurements will&#xD;
      be made (the biopsy will not be repeated for this last set of measurements). Patients will be&#xD;
      followed clinically and patient outcomes (mortality, duration of mechanical ventilation after&#xD;
      study entry) will be recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives. There is a single objective for this study, namely, to determine if early&#xD;
      administration of either EPA or HMB can prevent or reverse the development of respiratory&#xD;
      muscle weakness in critically ill, mechanically ventilated patients. The investigators plan&#xD;
      to randomize patients accepted into this protocol to administration of either a control&#xD;
      (saline enteral control solution), EPA administration (enteral EPA), HMB (enteral HMB), or a&#xD;
      combination of EPA and HMB. Drugs will be administered for 10 days and measurements of&#xD;
      diaphragm and quadriceps strength and size will be performed immediately before (day 0) and&#xD;
      immediately after (day 11) the period of drug administration. A third set of measurements&#xD;
      (diaphragm and quadriceps strength and size) will be performed on day 21. Vastus lateralis&#xD;
      muscle biopsies will also be taken on days 0 and 11; no biopsy will be performed for day 21&#xD;
      assessments. The investigators will also perform a chart review and assess ventilator&#xD;
      mechanics (respiratory system static compliance and inspiratory airway resistance) at the&#xD;
      time of the initial strength assessment. Patient outcomes (time on mechanical ventilation and&#xD;
      mortality) will also be recorded. The investigators would expect that mean diaphragm strength&#xD;
      and limb muscle strength measurements will be similar for four groups immediately before&#xD;
      initiation of drug administration. The hypothesis will be supported if, post drug&#xD;
      administration, diaphragm and limb muscle strength are higher for patients receiving EPA&#xD;
      and/or HMB than the control group receiving no active drug.&#xD;
&#xD;
      Study Design.&#xD;
&#xD;
      The basic study design is to:&#xD;
&#xD;
        1. measure magnetic stimulated Pdi twitch and quadriceps strength and size, obtain a muscle&#xD;
           biopsy from the vastus lateralis of the quadriceps, determine respiratory system&#xD;
           compliance, determine airway resistance, and perform a chart review,&#xD;
&#xD;
        2. randomize patients to treatment with either: control solutions (30 ml of enteral saline&#xD;
           solution every 12 hours), EPA (30 ml of enteral solution containing 1000 mg of EPA every&#xD;
           12 hours), HMB (30 ml of enteral solution containing 1500 mg HMB every 12 hours) or both&#xD;
           EPA (30 ml of enteral solution containing 1000 mg of EPA every 12 hours) and HMB (30 ml&#xD;
           of enteral solution containing 1500 mg HMB every 12 hours).&#xD;
&#xD;
        3. continue drugs for 10 days then&#xD;
&#xD;
        4. on day 11 remeasure magnetic stimulated Pdi twitch and quadriceps strength, repeat&#xD;
           measurements of diaphragm and quadriceps size (i.e. thickness), repeat the vastus&#xD;
           lateralis muscle biopsy, determine respiratory system compliance, determine airway&#xD;
           resistance, and perform a chart review.&#xD;
&#xD;
        5. on day 21 remeasure magnetic stimulated Pdi twitch and quadriceps strength, and repeat&#xD;
           measurements of diaphragm and quadriceps size (i.e. thickness), and perform another&#xD;
           chart review.&#xD;
&#xD;
      For each chart review the investigators will obtain the following information: age, sex,&#xD;
      diagnoses, reason for institution of mechanical ventilation, vital signs, bedside parameters&#xD;
      of mechanical ventilation use (including mode of ventilation, duration of ventilation, level&#xD;
      of oxygen, breath volume and rate, % triggered breaths), most recent arterial blood gas&#xD;
      values, chest radiograph readings, recorded assessments of limb muscle strength and mental&#xD;
      status.&#xD;
&#xD;
      Study Population. Adult patients requiring mechanical ventilation for more than 24 hours in&#xD;
      one of the University of Kentucky adult ICU's will be asked to participate. Patients will be&#xD;
      excluded if: (a) the physician caring for the patient determines that the patient is too&#xD;
      unstable to tolerate these measurements, (b) if the patient requires high dose pressors (more&#xD;
      than 15 mcg/min of norepinephrine or more than 15 mg/kg/min of dopamine), (c) if the patient&#xD;
      requires more than 80% FiO2 or more than 15 cm H2O of PEEP, (d) if the patient has a cardiac&#xD;
      pacemaker or implanted defibrillator, (e) if the patient has received neuromuscular blocking&#xD;
      agents within the 48 hours preceding testing or has a known preexisting muscular disease, (f)&#xD;
      if the patient has a recent history of variceal bleeding, and (g) if the patient is&#xD;
      excessively sedated or mentally obtunded as judged by an inability to follow verbal commands.&#xD;
      The investigators will also not study pregnant females, prisoners, or institutionalized&#xD;
      decisionally impaired patients.&#xD;
&#xD;
      The goals are to recruit 80 patients into the study over a 24 month period (5 patients/month,&#xD;
      20 patients per experimental group). The investigators will study patients regardless of sex,&#xD;
      race, or adult age. It is hoped that sufficient minorities and women will be studied so that&#xD;
      the subject population is representative of the general patient population, but the&#xD;
      investigators will be somewhat constrained by the numbers of available patients and the day&#xD;
      to day makeup of the patient population in the UK ICU's. Inclusion of minorities and women&#xD;
      will make the study results more generally applicable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Skeletal Muscle Strength for One of the Drugs Compared to Placebo</measure>
    <time_frame>By the second strength measurement (11 days)</time_frame>
    <description>The primary outcome to be assessed is whether skeletal muscle strength (diaphragm and limb) has changed at the end of the administration trial (i.e. at 11 days) for patients given one or both of the active drugs (EPA or HMB) as compared to strength measurements at 11 days for patients given the placebo.&#xD;
The number of subjects in each group for this section represent the numbers for whom it was possible to measure trans-diaphragmatic pressure after completion of treatment regimens and thereby calculate a change in this parameter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>Up to 50 Days</time_frame>
    <description>Total duration on mechanical ventilation up to 50 days after study entry. The number of subjects in each group for this section represent the numbers for whom it was possible to determine the duration of mechanical ventilation after completion of treatment regimens.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>Control, to be given saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: This group will be given saline (30 ml every 12 hours) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA, eicosapentaenoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be given 1000 mg EPA every 12 hours for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMB, hydroxymethylbutyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be given HMB (1500 mg) every 12 hours for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA and HMB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMB, hydroxymethylbutyrate</intervention_name>
    <description>Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days</description>
    <arm_group_label>EPA and HMB</arm_group_label>
    <arm_group_label>HMB, hydroxymethylbutyrate</arm_group_label>
    <other_name>This agent is an over the counter biopharmaceutical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPA, eicosapentaenoic acid</intervention_name>
    <description>EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
    <arm_group_label>EPA and HMB</arm_group_label>
    <arm_group_label>EPA, eicosapentaenoic acid</arm_group_label>
    <other_name>This is an over the counter biopharmaceutical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Control</description>
    <arm_group_label>Control, to be given saline solution</arm_group_label>
    <other_name>Salt water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients requiring mechanical ventilation for more than 24 hours in one of the&#xD;
             University of Kentucky adult ICU's&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The physician caring for the patient determines that the patient is too unstable to&#xD;
             tolerate these measurements,&#xD;
&#xD;
          -  If the patient requires high dose pressors (more than 15 mcg/min of norepinephrine or&#xD;
             more than 15 mg/kg/min of dopamine),&#xD;
&#xD;
          -  If the patient requires more than 80% FiO2 or more than 15 cm H2O of PEEP,&#xD;
&#xD;
          -  If the patient has a cardiac pacemaker or implanted defibrillator,&#xD;
&#xD;
          -  If the patient has received neuromuscular blocking agents within the 48 hours&#xD;
             preceding testing or has a known preexisting muscular disease,&#xD;
&#xD;
          -  If the patient has a recent history of variceal bleeding,&#xD;
&#xD;
          -  If the patient is excessively sedated or mentally obtunded as judged by an inability&#xD;
             to follow verbal commands.&#xD;
&#xD;
          -  We will not study pregnant females, prisoners, or institutionalized decisionally&#xD;
             impaired patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Supinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chandler Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <results_first_submitted>February 18, 2021</results_first_submitted>
  <results_first_submitted_qc>April 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2021</results_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Gerald Supinski</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>diaphragm</keyword>
  <keyword>limb muscle</keyword>
  <keyword>EPA</keyword>
  <keyword>HMB</keyword>
  <keyword>ICU patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT01270516/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT01270516/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT01270516/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control, to be Given Saline Solution</title>
          <description>Intervention: This group will be given saline (30 ml every 12 hours) for 10 days&#xD;
Saline: Control</description>
        </group>
        <group group_id="P2">
          <title>EPA, Eicosapentaenoic Acid</title>
          <description>This group will be given 1000 mg EPA every 12 hours for 10 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
        </group>
        <group group_id="P3">
          <title>HMB, Hydroxymethylbutyrate</title>
          <description>This arm will be given HMB (1500 mg) every 12 hours for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days</description>
        </group>
        <group group_id="P4">
          <title>EPA and HMB</title>
          <description>Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control, to be Given Saline Solution</title>
          <description>Intervention: This group will be given saline (30 ml every 12 hours) for 10 days&#xD;
Saline: Control</description>
        </group>
        <group group_id="B2">
          <title>EPA, Eicosapentaenoic Acid</title>
          <description>This group will be given 1000 mg EPA every 12 hours for 10 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
        </group>
        <group group_id="B3">
          <title>HMB, Hydroxymethylbutyrate</title>
          <description>This arm will be given HMB (1500 mg) every 12 hours for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days</description>
        </group>
        <group group_id="B4">
          <title>EPA and HMB</title>
          <description>Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="44" upper_limit="69"/>
                    <measurement group_id="B2" value="57" lower_limit="40" upper_limit="65"/>
                    <measurement group_id="B3" value="64" lower_limit="51" upper_limit="69"/>
                    <measurement group_id="B4" value="60" lower_limit="46" upper_limit="64"/>
                    <measurement group_id="B5" value="59" lower_limit="49" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transdiaphragmatic pressure</title>
          <units>cm H2O</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="4" upper_limit="9"/>
                    <measurement group_id="B2" value="4.7" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="B3" value="3.3" lower_limit="2" upper_limit="4.7"/>
                    <measurement group_id="B4" value="6" lower_limit="3" upper_limit="8"/>
                    <measurement group_id="B5" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Skeletal Muscle Strength for One of the Drugs Compared to Placebo</title>
        <description>The primary outcome to be assessed is whether skeletal muscle strength (diaphragm and limb) has changed at the end of the administration trial (i.e. at 11 days) for patients given one or both of the active drugs (EPA or HMB) as compared to strength measurements at 11 days for patients given the placebo.&#xD;
The number of subjects in each group for this section represent the numbers for whom it was possible to measure trans-diaphragmatic pressure after completion of treatment regimens and thereby calculate a change in this parameter.</description>
        <time_frame>By the second strength measurement (11 days)</time_frame>
        <population>Comparison of transdiaphragmatic twitch pressure (PdiTw), an index of strength, before and after treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Control, to be Given Saline Solution</title>
            <description>Intervention: This group will be given saline (30 ml every 12 hours) for 10 days&#xD;
Saline: Control</description>
          </group>
          <group group_id="O2">
            <title>EPA, Eicosapentaenoic Acid</title>
            <description>This group will be given 1000 mg EPA every 12 hours for 10 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
          </group>
          <group group_id="O3">
            <title>HMB, Hydroxymethylbutyrate</title>
            <description>This arm will be given HMB (1500 mg) every 12 hours for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EPA and HMB</title>
            <description>Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Skeletal Muscle Strength for One of the Drugs Compared to Placebo</title>
          <description>The primary outcome to be assessed is whether skeletal muscle strength (diaphragm and limb) has changed at the end of the administration trial (i.e. at 11 days) for patients given one or both of the active drugs (EPA or HMB) as compared to strength measurements at 11 days for patients given the placebo.&#xD;
The number of subjects in each group for this section represent the numbers for whom it was possible to measure trans-diaphragmatic pressure after completion of treatment regimens and thereby calculate a change in this parameter.</description>
          <population>Comparison of transdiaphragmatic twitch pressure (PdiTw), an index of strength, before and after treatment</population>
          <units>cm H2O</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.4" upper_limit="3.2"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0" upper_limit="3.2"/>
                    <measurement group_id="O4" value="0.7" lower_limit="-1.8" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Mechanical Ventilation</title>
        <description>Total duration on mechanical ventilation up to 50 days after study entry. The number of subjects in each group for this section represent the numbers for whom it was possible to determine the duration of mechanical ventilation after completion of treatment regimens.</description>
        <time_frame>Up to 50 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control, to be Given Saline Solution</title>
            <description>Intervention: This group will be given saline (30 ml every 12 hours) for 10 days&#xD;
Saline: Control</description>
          </group>
          <group group_id="O2">
            <title>EPA, Eicosapentaenoic Acid</title>
            <description>This group will be given 1000 mg EPA every 12 hours for 10 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
          </group>
          <group group_id="O3">
            <title>HMB, Hydroxymethylbutyrate</title>
            <description>This arm will be given HMB (1500 mg) every 12 hours for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EPA and HMB</title>
            <description>Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Mechanical Ventilation</title>
          <description>Total duration on mechanical ventilation up to 50 days after study entry. The number of subjects in each group for this section represent the numbers for whom it was possible to determine the duration of mechanical ventilation after completion of treatment regimens.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="8"/>
                    <measurement group_id="O2" value="7" lower_limit="7" upper_limit="13"/>
                    <measurement group_id="O3" value="6" lower_limit="4.5" upper_limit="10"/>
                    <measurement group_id="O4" value="6" lower_limit="3.8" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event information was collected over the time the patient was in the study, i.e. the 10 days during which treatments were being given.</time_frame>
      <desc>Adverse events included all deaths and any unusual event during the time of study treatment. All adverse events were reported and reviewed by the University of Kentucky Clinical Translational Center Data Safety and Monitoring Board. The patients in this study were seriously ill, with a high predicted mortality. The deaths that occurred in this population were expected based on their clinical presentations, and all had failure of one or more organ systems.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control, to be Given Saline Solution</title>
          <description>Intervention: This group will be given saline (30 ml every 12 hours) for 10 days&#xD;
Saline: Control</description>
        </group>
        <group group_id="E2">
          <title>EPA, Eicosapentaenoic Acid</title>
          <description>This group will be given 1000 mg EPA every 12 hours for 10 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
        </group>
        <group group_id="E3">
          <title>HMB, Hydroxymethylbutyrate</title>
          <description>This arm will be given HMB (1500 mg) every 12 hours for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days</description>
        </group>
        <group group_id="E4">
          <title>EPA and HMB</title>
          <description>Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.&#xD;
HMB, hydroxymethylbutyrate: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days&#xD;
EPA, eicosapentaenoic acid: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg hematoma</sub_title>
                <description>One patient developed a leg hematoma two days after the initial set of measurements. This patient, however, also developed other limb hematomas several weeks after the study was over.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emily Bradford, Clinical Trial Compliance Administrator</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859) 323-2973</phone>
      <email>emily.bradford@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

